Persuasion is often more effectual than force
The mission of the Advanced Liver Diseases Study Group is to become the premier epidemiology, clinical,
translational research, and treatment center for advanced liver diseases, cirrhosis, and portal hypertension in the
world. Additionally, the mission is to mentor and educate clinician investigators in the field of hepatology.
Please Take Attention, This
is just a Dummy Content,
Not a real facts about
The group is part of the Hepatic Vascular Cell
Signaling Lab and Hepatocellular Carcinoma Lab
programs as a major initiative involves collaboration
with scientists to establish translational research.The
activities of the Advanced Liver Diseases Study
Group span from population-based research that utilizes the extensive resources of the Rochester
Carcinoma Lab programs
- Understand the molecular and physiological mechanisms involved in cirrhosis and portal hypertension.
- Understand the mechanisms that underlie cirrhosis and portal hypertension by integrating basic science and
clinical research programs.
- Develop and validate non-invasive diagnostic tools to evaluate and quantitate severity of liver fibrosis and portal hypertension.
It is with truly mixed emotions that I announce the
departure of Philip E. Bourne, Ph.D., who will be
leaving his post as NIH’s first Associate Director for
Data Science to become the Stephenson Chair of Data Science, Director of the Data Science Institute, and
Professor in the Department of Biomedical Engineering at the University of Virginia, Charlottesville. I am happy
for Phil to have this exceptional opportunity, and know that UVA will be well served by his depth of knowledge in
data science. At the same time, I am saddened that NIH will be losing his prowess and passion for tackling the
opportunities and challenges of our increasingly data-driven biomedical research enterprise.